JMP Securities Lowers OptimizeRx (NASDAQ:OPRX) Price Target to $8.00

OptimizeRx (NASDAQ:OPRX) had its price target lowered by equities research analysts at JMP Securities from $16.00 to $8.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has a “market outperform” rating on the stock. JMP Securities’ price objective would indicate a potential upside of 30.08% from the company’s previous close.

A number of other analysts have also recently commented on OPRX. Barclays lowered their target price on shares of OptimizeRx from $15.00 to $11.00 and set an “equal weight” rating for the company in a research note on Monday, August 12th. B. Riley initiated coverage on OptimizeRx in a research report on Thursday, July 25th. They issued a “buy” rating and a $18.50 target price on the stock. Finally, Royal Bank of Canada lowered their price target on OptimizeRx from $17.00 to $14.00 and set an “outperform” rating for the company in a research report on Friday, August 16th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $12.90.

OptimizeRx Trading Up 5.3 %

Shares of NASDAQ:OPRX opened at $6.15 on Thursday. The business’s 50-day moving average is $6.75 and its 200 day moving average is $9.07. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.07 and a quick ratio of 3.07. OptimizeRx has a 1 year low of $5.04 and a 1 year high of $16.65. The firm has a market capitalization of $112.68 million, a P/E ratio of -6.15 and a beta of 1.32.

Institutional Investors Weigh In On OptimizeRx

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. BNP Paribas Financial Markets increased its holdings in OptimizeRx by 189.2% in the third quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock valued at $28,000 after buying an additional 2,414 shares in the last quarter. Quest Partners LLC increased its stake in shares of OptimizeRx by 15,965.6% in the 3rd quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock valued at $76,000 after purchasing an additional 9,739 shares in the last quarter. Greenwood Capital Associates LLC grew its holdings in OptimizeRx by 8.0% in the third quarter. Greenwood Capital Associates LLC now owns 67,356 shares of the company’s stock valued at $520,000 after purchasing an additional 4,999 shares during the period. Janney Montgomery Scott LLC acquired a new position in shares of OptimizeRx during the 3rd quarter worth approximately $810,000. Finally, Rice Hall James & Associates LLC lifted its position in shares of OptimizeRx by 24.0% during the 3rd quarter. Rice Hall James & Associates LLC now owns 615,441 shares of the company’s stock valued at $4,751,000 after buying an additional 119,306 shares in the last quarter. Institutional investors and hedge funds own 76.47% of the company’s stock.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.